What is Mazdutide?
Mazdutide (also known as IBI362 or LY3305677) is a GLP-1 receptor and glucagon receptor dual agonist, an oxyntomodulin analog developed by Eli Lilly and Innovent Biologics for research into obesity and metabolic disorders.
The peptide works by co-activating two distinct receptor systems. Through GLP-1 receptor agonism it influences appetite suppression, glucose-dependent insulin secretion, and slowed gastric emptying. Through glucagon receptor agonism it promotes increased energy expenditure and hepatic lipid metabolism. This dual mechanism acts on both food intake and metabolic rate simultaneously.
Mazdutide has an extended half-life suitable for once-weekly administration in research protocols. It is a research peptide and not an approved medicine.
The 20mg vial is a high-capacity presentation. Reconstituted with 2mL of bacteriostatic water it holds a 10mg/mL solution, which keeps every dose in the usual 3mg to 9mg research range inside a single U-100 syringe draw and yields roughly a full titration cycle from one vial.
Quick Reference
| Parameter | Value |
|---|---|
| Peptide Amount | 20mg |
| Recommended BAC Water | 2mL |
| Resulting Concentration | 10mg/mL (10000mcg/mL) |
| Typical Research Dose | 3mg - 9mg weekly |
| Frequency | Once weekly |
| Research Duration | 24-48 weeks |
Reconstitution Guide
Materials Needed
- Mazdutide 20mg lyophilized vial
- Bacteriostatic water (BAC water)
- Insulin syringes (U-100, 29-31 gauge)
- Alcohol swabs
- Sharps container
Step-by-Step Instructions
-
Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.
-
Clean the vial stoppers — Wipe the Mazdutide vial stopper and BAC water vial with alcohol swabs. Allow to dry completely.
-
Draw the BAC water — Using a sterile syringe, draw 2mL of bacteriostatic water. On a U-100 syringe this is two full 100-unit draws, so add the water in two passes.
-
Add water to peptide vial — Insert the needle into the Mazdutide vial and slowly inject the BAC water down the inside wall of the vial. Do not spray directly onto the powder.
-
Allow to dissolve — Mazdutide may take 5-10 minutes to fully dissolve. The larger powder cake in a 20mg vial can sit on the slower end of that window. Gently swirl occasionally — never shake vigorously.
-
Verify dissolution — The solution should be completely clear and colorless. If cloudy or particles remain, continue gentle swirling.
-
Label and store — Write the reconstitution date on the vial. Store in refrigerator immediately.
Dosage Protocol
Concentration Calculations
With 20mg peptide in 2mL BAC water:
- Concentration: 10mg/mL = 10000mcg/mL
- Per unit (U-100 syringe): 100mcg per unit
At 100mcg per unit the mental arithmetic is simple: the dose in milligrams multiplied by 10 gives the syringe units.
Common Dose Calculations
| Desired Dose | Draw Volume | Syringe Units |
|---|---|---|
| 3mg (3000mcg) | 0.30mL | 30 units |
| 4.5mg (4500mcg) | 0.45mL | 45 units |
| 6mg (6000mcg) | 0.60mL | 60 units |
| 9mg (9000mcg) | 0.90mL | 90 units |
Note: At 10mg/mL every dose through 9mg fits in one U-100 syringe, where the same 9mg dose from a 10mg vial at 5mg/mL needs 180 units across two draws. Researchers who prefer finer resolution at the low end can use 4mL of BAC water instead, giving 5mg/mL and doubling the volumes above — check that the vial has the headroom before adding that much water.
Suggested Titration Protocol
Mazdutide research protocols employ gradual dose escalation to assess tolerance, as the dual GLP-1/glucagon mechanism reaches higher effective doses than single GLP-1 agonists:
| Week | Dose | Syringe Units | Notes |
|---|---|---|---|
| 1-4 | 3mg | 30 units | Initial titration |
| 5-8 | 4.5mg | 45 units | First escalation |
| 9-16 | 6mg | 60 units | Second escalation |
| 17+ | 9mg | 90 units | Maintenance (if tolerated) |
Important Notes:
- Each dose level should be maintained for at least 4 weeks before escalation
- Not all research protocols require reaching maximum dose
- Dose escalation should be based on research objectives and tolerance
- A 20mg vial covers roughly six weekly 3mg doses, or a little over two weeks at the 9mg maintenance dose
Injection Guide
Subcutaneous Administration
- Clean the injection site with an alcohol swab
- Pinch a fold of skin (abdomen, thigh, or upper arm)
- Insert needle at 90° angle for most body types
- Inject slowly and steadily
- Wait 5-10 seconds before withdrawing needle
- Apply light pressure if needed — do not rub
Site Rotation
Rotate between these areas weekly:
- Abdomen (2+ inches from navel) — most common
- Outer thigh (front/outer area)
- Back of upper arm
Consistency tip: Administer on the same day each week to maintain steady levels.
Storage Requirements
Lyophilized (Powder Form)
- Temperature: -20°C (-4°F) or colder
- Duration: 2+ years
- Conditions: Protect from light and moisture
Reconstituted (Mixed with BAC Water)
- Temperature: 2-8°C (36-46°F) — standard refrigerator
- Duration: 4-6 weeks
- Conditions: Keep away from light, never freeze reconstituted solution
Important Storage Notes
- Mazdutide is sensitive to temperature — minimize time outside refrigeration
- Do not use if solution becomes cloudy, discolored, or contains particles
- Keep track of reconstitution date and discard after 6 weeks maximum
- At low doses a 20mg vial can outlast the 6-week window once mixed, so plan the reconstitution around the dose level in use
Research Considerations
Mechanism of Action
Mazdutide’s research applications stem from its dual GLP-1 and glucagon receptor agonism:
- GLP-1 receptor effects: Appetite suppression, glucose-dependent insulin secretion, slowed gastric emptying
- Glucagon receptor effects: Increased energy expenditure, hepatic lipid metabolism
- Combined effect: Simultaneous action on food intake and metabolic rate
- Metabolic: Observed effects on body weight and hepatic fat in research settings
Key Research Findings
Clinical research on mazdutide (IBI362) has demonstrated:
- Significant effects on body weight in participants with overweight or obesity
- Dose-dependent responses across the 3mg to 9mg weekly range
- Metabolic parameter changes consistent with the dual-agonist mechanism
Safety & Handling
General Precautions
- Use sterile technique for all preparations
- Never reuse needles or syringes
- Dispose of sharps properly in designated containers
- Store away from children and unauthorized persons
Research Considerations
- Mazdutide is for research purposes only
- Mazdutide is an investigational compound and is not an approved medicine
- Research-grade peptides are not equivalent to pharmaceutical preparations
- Follow institutional guidelines for peptide research
Sourcing for Research
Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.
Scientific References
- Ji L, et al. “Efficacy and safety of mazdutide in Chinese participants with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 2 trial.” 2024.
- Innovent Biologics / Eli Lilly mazdutide (IBI362) clinical development program, GLP-1/glucagon dual agonist studies.
Last updated: July 21, 2026
Disclaimer: This information is for educational and research purposes only. Mazdutide as a research peptide is not intended for human consumption. Mazdutide is an investigational compound and is not an approved medicine. Always follow applicable laws and institutional guidelines.